Quest Diagnostics Incorporated (DGX)
| Market Cap | 23.23B |
| Revenue (ttm) | 11.28B |
| Net Income (ttm) | 1.02B |
| Shares Out | 110.70M |
| EPS (ttm) | 9.05 |
| PE Ratio | 23.19 |
| Forward PE | 19.16 |
| Dividend | $3.44 (1.64%) |
| Ex-Dividend Date | Jul 8, 2026 |
| Volume | 1,349,740 |
| Open | 207.97 |
| Previous Close | 206.24 |
| Day's Range | 206.55 - 209.89 |
| 52-Week Range | 164.65 - 213.50 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 223.44 (+6.46%) |
| Earnings Date | Jul 23, 2026 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu... [Read more]
Financial Performance
In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $223.44, which is an increase of 6.46% from the latest price.
News
Quest Diagnostics’ Haystack MRD test receives New York SDOH approval
Quest Diagnostics (DGX) announced that the New York State Department of Health’s, or NYSDOH, Clinical Laboratory Evaluation Program, or CLEP, has approved the company’s Haystack MRD test, a circulatin...
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /P...
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the thr...
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
SECAUCUS, N.J., June 17, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 finan...
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
SECAUCUS, N.J., June 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
Quest Diagnostics management to meet with Oppenheimer
Meeting to be held in New Jersey on June 8 hosted by Oppenheimer.
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend ...
Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
Quest Diagnostics Prices $500 Million of Senior Notes
SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering...
Quest Diagnostics price target raised to $225 from $220 at Truist
Truist raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $220 and keeps a Hold rating on the shares after its Q1 earnings beat. Core trends were…
Quest Diagnostics price target raised to $220 from $210 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Quest Diagnostics (DGX) to $220 from $210 and keeps a Neutral rating on the shares.
Quest Diagnostics price target raised to $229 from $224 at Baird
Baird raised the firm’s price target on Quest Diagnostics (DGX) to $229 from $224 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Quest Diagnostics price target raised to $245 from $225 at BofA
BofA raised the firm’s price target on Quest Diagnostics (DGX) to $245 from $225 and keeps a Buy rating on the shares after Q1 results came in well ahead of…
Quest Diagnostics price target raised to $230 from $225 at Barclays
Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $230 from $225 and keeps an Overweight rating on the shares. The company’s “solid beat/raise” quarter underscores the momentum…
Quest Diagnostics price target raised to $225 from $210 at Evercore ISI
Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $210 and keeps an In Line rating on the shares after the company reported a “solid”…
Quest Diagnostics price target raised to $225 from $220 at Jefferies
Jefferies raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $220 and keeps a Buy rating on the shares following a beat on sales and EPS, led…
Quest Diagnostics Earnings Call Transcript: Q1 2026
Q1 2026 saw over 9% revenue growth and a 13% rise in adjusted EPS, driven by strong organic demand, advanced diagnostics, and productivity gains from AI and automation. Full-year guidance for revenue and EPS was raised, with continued investment in innovation and digital transformation.
Quest Diagnostics Earnings release: Q1 2026
Quest Diagnostics released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Quest Diagnostics Slides: Q1 2026
Quest Diagnostics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Quest Diagnostics Quarterly report: Q1 2026
Quest Diagnostics has published its Q1 2026 quarterly earnings report on April 21, 2026.
Quest Diagnostics raises full-year forecast, posts strong quarter on testing demand
Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing.
Quest Diagnostics raises FY26 adjusted EPS view to $10.63-$10.83
Previous view $10.50-$10.70. Consensus $10.63. Raises revenue view to $11.78B-$11.9B from $11.7B-$11.82B, consensus $11.76B.
Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted dilute...
City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES...
Quest Diagnostics target cut, added to ‘Tactical Outperform’ list at Evercore
Evercore ISI lowered the firm’s price target on Quest Diagnostics (DGX) to $210 from $220 and keeps an In Line rating on the shares as the firm made several price…